Brief: Nexstim Gets FDA Clearance In U.S. For OCD Treatment
March 23 (Reuters) - Nexstim Oyj NXTMH.HE: NBS SYSTEM 6 GAINS FDA CLEARANCE FOR TREATMENT OF OBSESSIVE COMPULSIVE DISORDER (OCD) NBS 6 IS ALSO FDA-CLEARED FOR PRE-SURGICAL MAPPING OF SPEECH AND MOTOR CORTICES OF BRAIN ANNOUNCES LAUNCH OF NBS 6 SYSTEM FOR TREATMENT OF OBSESSIVE COMPULSIVE DISORDER (OCD) IN UNITED STATES Source text: (Full Story) Further company coverage: NXTMH.HE (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Nexstim Oyj
See all newsBrief: Nexstim Receives Order For NBS 6 System From Finnish Hospital
Brief: Nexstim Gets Order for NBS 6 System From European Hospital
Brief: US University Customer Purchases Nexstim NBS 6 For Research Purposes
Brief: Nexstim Gets NBS 6 System Order For European Hospital
Brief: Nexstim Gets Order From New U.S. Customer